Valuation: EnteroMedics Inc

Market Cap 15.93M 13.76M 12.95M 11.77M 22.13M 1.53B 22.46M 152M 59.51M 763M 59.81M 58.52M 2.54B P/E 2026 *
-3.22x
P/E 2027 * -2.48x
Enterprise Value 15.93M 13.76M 12.95M 11.77M 22.13M 1.53B 22.46M 152M 59.51M 763M 59.81M 58.52M 2.54B EV / Sales 2026 *
106x
EV / Sales 2027 * 63.7x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 130K 122K 111K 208K 14.37M 211K 1.43M 560K 7.19M 563K 551K 23.94M 250K 216K 203K 185K 347K 23.95M 352K 2.38M 934K 11.98M 939K 918K 39.9M
Net income -4.89M -4.22M -3.97M -3.61M -6.79M -469M -6.89M -46.61M -18.27M -234M -18.36M -17.96M -781M -7.77M -6.71M -6.31M -5.74M -10.79M -744M -10.95M -74.06M -29.02M -372M -29.17M -28.54M -1.24B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-